Supplier Development at Astra Zeneca, China: Streamlining the Clinical Supply Chain through improved supplier capabilities

Bhardwaj, Saurabh (2011) Supplier Development at Astra Zeneca, China: Streamlining the Clinical Supply Chain through improved supplier capabilities. [Dissertation (University of Nottingham only)] (Unpublished)

[img] PDF (MBA Dissertation) - Registered users only - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
Download (9MB)


The development of a pharmaceutical product, on average, takes about 12 – 15 years and is rife with its unique set of challenges. Study Management, which is a rather important function in the R & D process, deals with setting up and completing clinical trials in a timely and cost effective manner. The clinical supply chain (C- Chain) which is just one of its constituent elements shall be our area of focus.

A robust and effective clinical supply chain ensures that investigational product reaches the investigation sites in a timely, cost effective and safe manner. While this might seem like an easy task, managing multiple clinical studies, which have their own unique logistics considerations and are carried out across multiple locations globally, can be quite a challenge and an area where companies might make sizeable savings or loses. Further, the unique environment in emerging countries and the regulatory pressures there are seen to add to the level of complexity.

With these issues in the backdrop, we take a closer look at the Clinical Supply Chain at Astra Zeneca, China (AZ). The distribution process is defined and its intricacies are outlined through a detailed analysis of the system. Further, the role of service partners in developing an efficient supply chain is assessed; their capabilities and performance are also evaluated. The report is structured around developing a key supplier – Fisher Clinical Services and a greater emphasis has been placed on their processes and areas where supplier development is warranted.

Additionally, the case looks at a new distribution model that AZ has commissioned in the recent past and its applicability to China is assessed. Finally, we highlight the importance of a robust C- Chain and the potential benefits of driving efficiency in the Study Management function, which is seen as a key contributor to the value of R & D at AZ and the value of the portfolio.

Item Type: Dissertation (University of Nottingham only)
Depositing User: EP, Services
Date Deposited: 10 Nov 2011 15:04
Last Modified: 21 Mar 2022 16:09

Actions (Archive Staff Only)

Edit View Edit View